.After elevating $170 million back in February, metabolic disease-focused BioAge Labs has actually filed to debut on the public market.The Eli Lilly-partnered biotech plan to specify on the Nasdaq under the sign “BIOA,” according to records filed along with the Stocks and Swap Payment. The company has actually certainly not openly discussed an expected financial quantity for the offering.The clinical-stage firm proclaims lead candidate azelaprag, a by mouth delivered little molecule slated to get in phase 2 screening in combo with semaglutide– sold by Novo Nordisk under brand name Wegovy for weight management– in the 1st fifty percent of upcoming year. Semaglutide is additionally offered as Ozempic and Rybelsus by Novo for diabetes.
Apelin receptor agonist azelaprag is actually developed to combine effectively with GLP-1 medications, increasing weight loss while keeping muscle mass. The investigational drug was located to be well-tolerated amongst 265 individuals throughout eight period 1 tests, according to BioAge.Previously, BioAge amassed the support of Lilly to run a test combining azelaprag along with the Huge Pharma’s GLP-1/ GIP receptor agonist tirzepatide, which is industried for diabetes as Mounjaro and also Zepbound for weight management. The partners are actually presently administering a period 2 test of azelaprag as well as tirzepatide, along with topline results assumed in the 3rd quarter of 2025.The biotech is actually additionally planning a the hormone insulin sensitivity proof-of-concept test assessing azelaprag as a monotherapy in the very first one-half of next year to assist possible indication development.
Additionally, the business intends to ask the FDA for consent in the 2nd one-half of 2025 to release individual screening for an NLRP3 prevention targeting metabolic illness and neuroinflammation.BioAge’s foreseed transfer to everyone market observes a minor uptick in considered biotech IPOs coming from Bicara Therapies and also Zenas Biopharma. Zooming out, the current IPO yard is a “blended image,” with top notch firms still debuting on the general public markets, simply in lowered varieties, according to PitchBook.